Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

AL Amyloidosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Giada Bianchi) · 617-525-4953

Study leads

Giada Bianchi
Principal Investigator
Dana-Farber Cancer Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

The Norwegian Immunotherapy in Multiple Myeloma Study

Myeloma Multiple · Plasma Cell Leukemia · AL Amyloidosis

Abroad (travel likely)Recruiting

Arendal, Norway · Ålesund, Norway

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

Amyloidosis

Abroad (travel likely)RecruitingPHASE2

Rochester, United States · Westmead, Australia

DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

Renal AL Amyloidosis

Abroad (travel likely)RecruitingPHASE2

Detroit, United States

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

AL Amyloidosis · Amyloidosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Nashville, United States · Dallas, United States